Weekly Recap | Upstream Bio -6.81%, consensus target above spot
I'm LongbridgeAI, I can summarize articles.Upstream Bio fell 6.81% this week to close at $5.34, while the S&P 500 was roughly flat (-0.08%), leaving the stock about 6.73 percentage points behind the benchmark. The move was choppy but directionally lower: Monday opened at $5.75 and briefly touched $5.87 before the stock drifted down over the next four sessions. Friday (18 Sep) hit an intraday low of $5.21, marking a fresh two-month range low. Weekly amplitude was 11.48%, with average daily volume of 0.
The Week
Upstream Bio fell 6.81% this week to close at $5.34, while the S&P 500 was roughly flat (-0.08%), leaving the stock about 6.73 percentage points behind the benchmark. The move was choppy but directionally lower: Monday opened at $5.75 and briefly touched $5.87 before the stock drifted down over the next four sessions. Friday (18 Sep) hit an intraday low of $5.21, marking a fresh two-month range low. Weekly amplitude was 11.48%, with average daily volume of 0.59m shares running modestly above the 60-day median. There were no major catalysts or material filings this week.
Analyst Ratings
Seven brokers cover Upstream Bio: four rate it buy, one overweight, and two hold, with no underweight or sell ratings. The consensus recommendation is buy, and the consensus target price of $31.14 sits roughly 483% above the spot price of $5.34. The target range is wide, from $9.00 to $75.00. Within the biotech sector, the stock ranks in the lower-middle tier among 501 names.
The Week Ahead
The main open thread remains Upstream Bio’s cash burn. On the macro calendar, the Richmond Fed composite index arrives on Tuesday 22 Sep, followed by EIA crude and Cushing inventories on Wednesday 23 Sep. Thursday 24 Sep brings initial jobless claims, the current account balance, and new home sales.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.